Targeted therapies for ER+/HER2-metastatic breast cancer

被引：56

作者：

Yamamoto-Ibusuki, Mutsuko ^{[1
]}

Arnedos, Monica ^{[2
,3
]}

Andre, Fabrice ^{[2
,3
]}

机构：

[1] Kumamoto Univ, Grad Sch Med Sci, Dept Breast & Endocrine Surg, Kumamoto, Japan

[2] Dept Med Oncol, F-94800 Villejuif, France

[3] INSERM, Unit U981, Villejuif, France

来源：

BMC MEDICINE | 2015年 / 13卷

关键词：

Breast cancer; Targeted therapy; Cancer genome; Endocrine therapy resistance; HISTONE DEACETYLASE INHIBITORS; EVEROLIMUS PLUS EXEMESTANE; KINASE; 4/6; INHIBITOR; RANDOMIZED PHASE-II; ESTROGEN-RECEPTOR; POSTMENOPAUSAL WOMEN; ENDOCRINE THERAPY; PI3K INHIBITOR; CYCLIN D; RESISTANT;

D O I：

10.1186/s12916-015-0369-5

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The majority of breast cancers present with estrogen receptor (ER)-positive and human epidermal growth factor receptor (HER2)-negative features and might benefit from endocrine therapy. Although endocrine therapy has notably evolved during the last decades, the invariable appearance of endocrine resistance, either primary or secondary, remains an important issue in this type of tumor. The improvement of our understanding of the cancer genome has identified some promising targets that might be responsible or linked to endocrine resistance, including alterations affecting main signaling pathways like PI3K/Akt/mTOR and CCND1/CDK4-6 as well as the identification of new ESR1 somatic mutations, leading to an array of new targeted therapies that might circumvent or prevent endocrine resistance. In this review, we have summarized the main targeted therapies that are currently being tested in ER+ breast cancer, the rationale behind them, and the new agents and combinational treatments to come.

引用

页数：12

共 79 条

[31] Binding of Ras to phosphoinositide 3-kinase p110α is required for Ras-driven tumorigenesis in mice [J].

Gupta, Surbhi ;

Ramjaun, Antoine R. ;

Haiko, Paula ;

Wang, Yihua ;

Warne, Patricia H. ;

Nicke, Barbara ;

Nye, Emma ;

Stamp, Gordon ;

Alitalo, Kari ;

Downward, Julian .

CELL, 2007, 129 (05) :957-968

[32] Hallmarks of Cancer: The Next Generation [J].

Hanahan, Douglas ;

Weinberg, Robert A. .

CELL, 2011, 144 (05) :646-674

[33] PI3K in cancer-stroma interactions: bad in seed and ugly in soil [J].

Hirsch, E. ;

Ciraolo, E. ;

Franco, I. ;

Ghigo, A. ;

Martin, M. .

ONCOGENE, 2014, 33 (24) :3083-3090

[34]

Hortobagyi GN, 2013, J CLIN ONCOL S

[35] Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: a prospective study [J].

Iwase, H. ;

Yamamoto, Y. ;

Yamamoto-Ibusuki, M. ;

Murakami, K-I ;

Okumura, Y. ;

Tomita, S. ;

Inao, T. ;

Honda, Y. ;

Omoto, Y. ;

Iyama, K-I .

BRITISH JOURNAL OF CANCER, 2013, 109 (06) :1537-1542

[36] Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer [J].

Jeselsohn, Rinath ;

Yelensky, Roman ;

Buchwalter, Gilles ;

Frampton, Garrett ;

Meric-Bernstam, Funda ;

Gonzalez-Angulo, Ana Maria ;

Ferrer-Lozano, Jaime ;

Perez-Fidalgo, Jose A. ;

Cristofanilli, Massimo ;

Gomez, Henry ;

Arteaga, Carlos L. ;

Giltnane, Jennifer ;

Balko, Justin M. ;

Cronin, Maureen T. ;

Jarosz, Mirna ;

Sun, James ;

Hawryluk, Matthew ;

Lipson, Doron ;

Otto, Geoff ;

Ross, Jeffrey S. ;

Dvir, Addie ;

Soussan-Gutman, Lior ;

Wolf, Ido ;

Rubinek, Tamar ;

Gilmore, Lauren ;

Schnitt, Stuart ;

Come, Steven E. ;

Pusztai, Lajos ;

Stephens, Philip ;

Brown, Myles ;

Miller, Vincent A. .

CLINICAL CANCER RESEARCH, 2014, 20 (07) :1757-1767

[37] CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment [J].

Jin, Y ;

Desta, Z ;

Stearns, V ;

Ward, B ;

Ho, H ;

Lee, KH ;

Skaar, T ;

Storniolo, AM ;

Li, L ;

Araba, A ;

Blanchard, R ;

Nguyen, A ;

Ullmer, L ;

Hayden, J ;

Lemler, S ;

Weinshilboum, RM ;

Rae, JM ;

Hayes, DF ;

Flockhart, DA .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (01) :30-39

[38]

Juric J.R. Dejan., 2012, Cancer Res, V72, P1

[39] Comprehensive molecular portraits of human breast tumours [J].

Koboldt, Daniel C. ;

Fulton, Robert S. ;

McLellan, Michael D. ;

Schmidt, Heather ;

Kalicki-Veizer, Joelle ;

McMichael, Joshua F. ;

Fulton, Lucinda L. ;

Dooling, David J. ;

Ding, Li ;

Mardis, Elaine R. ;

Wilson, Richard K. ;

Ally, Adrian ;

Balasundaram, Miruna ;

Butterfield, Yaron S. N. ;

Carlsen, Rebecca ;

Carter, Candace ;

Chu, Andy ;

Chuah, Eric ;

Chun, Hye-Jung E. ;

Coope, Robin J. N. ;

Dhalla, Noreen ;

Guin, Ranabir ;

Hirst, Carrie ;

Hirst, Martin ;

Holt, Robert A. ;

Lee, Darlene ;

Li, Haiyan I. ;

Mayo, Michael ;

Moore, Richard A. ;

Mungall, Andrew J. ;

Pleasance, Erin ;

Robertson, A. Gordon ;

Schein, Jacqueline E. ;

Shafiei, Arash ;

Sipahimalani, Payal ;

Slobodan, Jared R. ;

Stoll, Dominik ;

Tam, Angela ;

Thiessen, Nina ;

Varhol, Richard J. ;

Wye, Natasja ;

Zeng, Thomas ;

Zhao, Yongjun ;

Birol, Inanc ;

Jones, Steven J. M. ;

Marra, Marco A. ;

Cherniack, Andrew D. ;

Saksena, Gordon ;

Onofrio, Robert C. ;

Pho, Nam H. .

NATURE, 2012, 490 (7418) :61-70

[40] The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with ER plus , aromatase inhibitor ( AI) resistant advanced or metastatic breast cancer - Part I results [J].

Krop, Ian ;

Johnston, Stephen ;

Mayer, Ingrid A. ;

Dickler, Maura ;

Ganju, Vinod ;

Forero-Torres, Andres ;

Melichar, Bohuslav ;

Morales, Serafin ;

de Boer, Richard ;

Gendreau, Steven ;

Derynck, Mika ;

Lackner, Mark ;

Spoerke, Jill ;

Yeh, Ru-Fang ;

Levy, Gallia ;

Ng, Vivian ;

O'Brien, Carol ;

Savage, Heidi ;

Xiao, Yuanyuan ;

Wilson, Timothy ;

Lee, Soo Chin ;

Petrakova, Katarina ;

Vallentin, Susanne ;

Yardley, Denise ;

Ellis, Matthew ;

Piccart, Martine ;

Perez, Edith A. ;

Winer, Eric ;

Schmid, Peter .

CANCER RESEARCH, 2015, 75

← 1 2 3 4 5 6 7 8 →